A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...

Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

NeuroDex gets research grant from The Michael J. Fox Foundation to develop blood-based biomarker for Parkinson’s disease: Natick, Massachusetts Friday, November 15, 2024, 17:00 ...

Patients from Part 2 will be evaluated for the progression of motor and non-motor symptoms ... validated anti-a-syn active ...

Brain disorders like Parkinson's or Alzheimer's Disease start to develop in patients much earlier than when their first clinical symptoms appear. Treating patients at these early stages could slow or ...

While Parkinson’s disease (PD) has a large and highly generalised therapeutic ... such as alpha-synuclein aggregation and ...